115 related articles for article (PubMed ID: 15380672)
1. Anti-oxidants and apoptosis: attenuation of doxorubicin induced cardiomyopathy by carvedilol.
Armstrong SC
J Mol Cell Cardiol; 2004 Oct; 37(4):817-21. PubMed ID: 15380672
[No Abstract] [Full Text] [Related]
2. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro.
Spallarossa P; Garibaldi S; Altieri P; Fabbi P; Manca V; Nasti S; Rossettin P; Ghigliotti G; Ballestrero A; Patrone F; Barsotti A; Brunelli C
J Mol Cell Cardiol; 2004 Oct; 37(4):837-46. PubMed ID: 15380674
[TBL] [Abstract][Full Text] [Related]
3. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy.
Santos DL; Moreno AJ; Leino RL; Froberg MK; Wallace KB
Toxicol Appl Pharmacol; 2002 Dec; 185(3):218-27. PubMed ID: 12498738
[TBL] [Abstract][Full Text] [Related]
4. Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy.
Chen YL; Chung SY; Chai HT; Chen CH; Liu CF; Chen YL; Huang TH; Zhen YY; Sung PH; Sun CK; Chua S; Lu HI; Lee FY; Sheu JJ; Yip HK
J Pharmacol Exp Ther; 2015 Dec; 355(3):516-27. PubMed ID: 26511374
[TBL] [Abstract][Full Text] [Related]
5. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats.
Matsui H; Morishima I; Numaguchi Y; Toki Y; Okumura K; Hayakawa T
Life Sci; 1999; 65(12):1265-74. PubMed ID: 10503942
[TBL] [Abstract][Full Text] [Related]
6. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity.
Oliveira PJ; Bjork JA; Santos MS; Leino RL; Froberg MK; Moreno AJ; Wallace KB
Toxicol Appl Pharmacol; 2004 Oct; 200(2):159-68. PubMed ID: 15476868
[TBL] [Abstract][Full Text] [Related]
7. Carvedilol: just another Beta-blocker or a powerful cardioprotector?
Carreira RS; Monteiro P; Gon Alves LM; Providência LA
Cardiovasc Hematol Disord Drug Targets; 2006 Dec; 6(4):257-66. PubMed ID: 17378771
[TBL] [Abstract][Full Text] [Related]
8. Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol.
Pereira GC; Silva AM; Diogo CV; Carvalho FS; Monteiro P; Oliveira PJ
Curr Pharm Des; 2011; 17(20):2113-29. PubMed ID: 21718248
[TBL] [Abstract][Full Text] [Related]
9. Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase.
Octavia Y; Kararigas G; de Boer M; Chrifi I; Kietadisorn R; Swinnen M; Duimel H; Verheyen FK; Brandt MM; Fliegner D; Cheng C; Janssens S; Duncker DJ; Moens AL
J Cell Mol Med; 2017 Dec; 21(12):3277-3287. PubMed ID: 28608983
[TBL] [Abstract][Full Text] [Related]
10. Fighting doxorubicin-induced cardiotoxicity with adiponectin.
McTiernan CF
Cardiovasc Res; 2011 Feb; 89(2):262-4. PubMed ID: 21156822
[No Abstract] [Full Text] [Related]
11. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
12. Yogurt Containing the Probacteria Lactobacillus acidophilus Combined with Natural Antioxidants Mitigates Doxorubicin-Induced Cardiomyopathy in Rats.
Abu-Elsaad NM; Abd Elhameed AG; El-Karef A; Ibrahim TM
J Med Food; 2015 Sep; 18(9):950-9. PubMed ID: 25590792
[TBL] [Abstract][Full Text] [Related]
13. Protection from doxorubicin-induced cardiomyopathy using the modified anthracycline N-benzyladriamycin-14-valerate (AD 198).
Cai C; Lothstein L; Morrison RR; Hofmann PA
J Pharmacol Exp Ther; 2010 Oct; 335(1):223-30. PubMed ID: 20668052
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity.
Fan GC; Zhou X; Wang X; Song G; Qian J; Nicolaou P; Chen G; Ren X; Kranias EG
Circ Res; 2008 Nov; 103(11):1270-9. PubMed ID: 18948619
[TBL] [Abstract][Full Text] [Related]
15. Neuregulin-1 attenuates doxorubicin-induced autophagy in neonatal rat cardiomyocytes.
An T; Huang Y; Zhou Q; Wei BQ; Zhang RC; Yin SJ; Zou CH; Zhang YH; Zhang J
J Cardiovasc Pharmacol; 2013 Aug; 62(2):130-7. PubMed ID: 23519142
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway.
Kim KH; Oudit GY; Backx PH
J Pharmacol Exp Ther; 2008 Jan; 324(1):160-9. PubMed ID: 17928571
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase.
Spallarossa P; Altieri P; Garibaldi S; Ghigliotti G; Barisione C; Manca V; Fabbi P; Ballestrero A; Brunelli C; Barsotti A
Cardiovasc Res; 2006 Feb; 69(3):736-45. PubMed ID: 16213474
[TBL] [Abstract][Full Text] [Related]
18. Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
Kalay N; Basar E; Ozdogru I; Er O; Cetinkaya Y; Dogan A; Inanc T; Oguzhan A; Eryol NK; Topsakal R; Ergin A
J Am Coll Cardiol; 2006 Dec; 48(11):2258-62. PubMed ID: 17161256
[TBL] [Abstract][Full Text] [Related]
19. Carvedilol for anthracycline cardiomyopathy prevention.
Florenzano F; Salman P
J Am Coll Cardiol; 2007 May; 49(21):2142; author reply 2142-3. PubMed ID: 17531665
[No Abstract] [Full Text] [Related]
20. Doxorubicin mediated cardiotoxicity in rats: protective role of felodipine on cardiac indices.
Gandhi H; Patel VB; Mistry N; Patni N; Nandania J; Balaraman R
Environ Toxicol Pharmacol; 2013 Nov; 36(3):787-95. PubMed ID: 23958971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
